Theravance Biopharma, Inc. has recently released its 10-Q report, providing an in-depth look at the company's financial performance and operations. The company primarily focuses on developing and commercializing medicines, with a specific emphasis on chronic obstructive pulmonary disease (COPD) and neurogenic orthostatic hypotension (nOH). Its flagship product, YUPELRI, is a once-daily, nebulized long-acting muscarinic antagonist approved for the maintenance treatment of COPD in the United States.
In the 10-Q report, the company discusses its strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. As of June 30, 2025, Theravance Biopharma was eligible to receive potential global sales and regulatory milestone payments from Viatris of up to $205.0 million, with $160.0 million associated with YUPELRI monotherapy and $45.0 million associated with future potential combination products.
Additionally, the report provides updates on Ampreloxetine (TD-9855), an investigational norepinephrine reuptake inhibitor for the treatment of symptomatic nOH in patients with Multiple System Atrophy (MSA). Despite the Phase 3 clinical study not meeting its primary endpoint, the company held a Type C meeting with the FDA and outlined a path to a New Drug Application (NDA) filing with one additional Phase 3 clinical study (CYPRESS) in MSA patients with symptomatic nOH.
Furthermore, the report highlights the company's economic interests and other assets, including the completion of the sale of its equity interests in Theravance Respiratory Company, LLC to Royalty Pharma for approximately $1.11 billion in upfront cash. As of June 30, 2025, Theravance Biopharma was eligible to receive potential milestone payments from Royalty Pharma, with $150.0 million in potential milestone payments remaining available to the company.
Today the company's shares have moved 4.15% to a price of $12.415. For the full picture, make sure to review Theravance Biopharma's 10-Q report.
